Biological therapy for the treatment of rheumatic diseases;Biologikatherapie bei rheumatologischen erkrankungen

Internist

Volumn 49, Issue 8, 2008, Pages 938-946

  Pierer, M ^a   Baerwald, C ^a  

^a Medizinische Klinik and Poliklinik II   (Germany)

Author keywords

Ankylosing spondylitis; Biological therapy; Psoriatic arthritis; Rheumatoid arthritis; Vasculitis

Indexed keywords

ABATACEPT; ADALIMUMAB; COLONY STIMULATING FACTOR; CYTOKINE; ETANERCEPT; INFLIXIMAB; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; BIOLOGICAL THERAPY; COMBINATION CHEMOTHERAPY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MONOTHERAPY; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TREATMENT INDICATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; COLLAGEN DISEASES; DRUG THERAPY, COMBINATION; HUMANS; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-1; RHEUMATIC DISEASES; SPONDYLITIS, ANKYLOSING; STILL'S DISEASE, ADULT-ONSET; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 48849115457     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-008-2059-2     Document Type: Review

References (32)

1. Abrams JR, Lebwohl MG, Guzzo CA et al. (1999) CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103: 1243-1252
2. Aringer M, Smolen JS (2004) Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 13: 344-347
3. Askling J, Bongartz T (2008) Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 20: 334-339
4. Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369: 1379-1390
5. Brezinschek HP, Hofstaetter T, Leeb BF et al. (2008) Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate. Curr Opin Rheumatol 20: 295-299
6. Chitale S, Moots R (2008) Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 8: 115-122
7. Chung ES, Packer M, Lo KA et al. (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 107: 3133-3140
8. Davis JC Jr, Mease PJ (2007) Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic. Semin Arthritis Rheum 2007 Dec 29 [Epub ahead of print]
9. Davis JC Jr, Van der Heijde DM, Braun J et al. (2008) Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67: 346-352
10. Dixon WG, Watson KD, Lunt M et al. (2007) Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56: 2905-2912
11. Dörner T, Burmester GR (2008) New approaches of B-cell-directed therapy: beyond rituximab. Curr Opin Rheumatol 20: 263-268
12. Finckh A, Gabay C (2008) At the horizon of innovative therapy in rheumatology: new biologic agents. Curr Opin Rheumatol 20: 269-275
13. Furst DE, Breedveld FC, Kalden JR et al. (2007) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis [Suppl 3] 66: III2-III22
14. Gartlehner G, Hansen RA, Jonas BL et al. (2008) Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin Rheumatol 27: 67-76
15. Gödde A, Müller-Ladner U (2006) Therapy for secondary arthropathies: from psoriasis and Reiter's disease to hemochromatosis. Internist (Berl) 47: 1263-1268
16. Harrison MJ, Dixon WG, Watson KD et al. (2008) Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNF{alpha} therapy. Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2008 Apr 2 [Epub ahead of print]]
17. Heiberg MS, Nordvag BY, Mikkelsen K et al. (2005) The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 52: 2506-2512
18. Horneff G (2006) Biologics for treatment of juvenile idiopathic arthritis. Consensus statement of the 7th Worlitzer Expertengesprache 2004 for the German Arbeitsgemeinschaft Kinder- und Jugendrheumatologie. Z Rheumatol 65: 152-158
19. Hyrich KL, Lunt M, Watson KD et al. (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56: 13-20
20. Lee RW, D'Cruz DP (2008) Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis. Drugs 68: 747-770
21. Manger B, Michels H, Nüsslein HG et al. (2007) Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses. Z Rheumatol 66: 72-75
22. Patkar NM, Teng GG, Curtis JR et al. (2008) Association of infections and tuberculosis with antitumor necrosis factor alpha therapy. Curr Opin Rheumatol 20: 320-326
23. Punzi L, Podswiadek M, Sfriso P et al. (2007) Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmun Rev 6: 524-528
24. Scherer HU, Burmester GR (2006) Biologicals in the treatment of rheumatic diseases. Dtsch Med Wochenschr 131: 2279-2285
25. Sibilia J, Westhovens R (2007) Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol 25: S46-S56
26. Smolen JS, Aletaha D (2008) Activity assessments in rheumatoid arthritis. Curr Opin Rheumatol 20: 306-313
27. Smolen JS, Aletaha D, Koeller M et al. (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370: 1861-1874
28. Soriano ER, McHugh NJ (2006) Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 33: 1422-1430
29. Strand V, Kimberly R, Isaacs JD (2007) Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 6: 75-92
30. Toussirot E, Wendling D (2007) The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin Pharmacother 8: 2089-2107
31. Van der Kooij SM, Allaart CF, Dijkmans BA et al. (2008) Innovative treatment strategies for patients with rheumatoid arthritis. Curr Opin Rheumatol 20: 287-294
32. Vincenti F (2008) Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol 121: 299-306